Facebook
Twitter
LinkedIn
Forward
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3
|
This session covers the employer health benefit landscape and how it has changed over the last five years due to COVID, new treatments, technology, and competition.
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
Obesity has emerged as a global epidemic with significant repercussions for public health due to its strong relationship with diseases such as from insulin resistance, Type 2 diabetes, hypertension
|
The session will begin by providing a general overview of the prevalence and epidemiology of nonalcoholic fatty liver disease.
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
Incretin medications, like semaglutide and tirzepatide, suppress appetite and delay gastric emptying, facilitating weight loss and begging the question of the need for concurrent behavior change th
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
In this session, co-presented by a primary care and an obesity-focused tertiary care provider, we will review barriers and facilitators to pediatric obesity treatment in primary and tertiary care s
|